TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria for study and fellow eye:~• Patients with visual impairment secondary to central retinal vein occlusion (CRVO) with a BCVA between 24 and 73 letters in one eye and at least 35 letters in the other eye.~Exclusion Criteria:~* Pregnant or nursing women or women of child bearing potential unless using an effective contraception~  - Stroke or myocard infarction within 3 months prior to study~* History of malignancy within the past 5 years~* Uncontrolled hypertension~* Active infection or inflammation in any eye~* use of corticosteroids for at least 30 days in the last 6 months~* treatment with anti-angiogenic drugs in any eye within last 3 months~* Panretinal or focal/drid laser photocoagulation within the last 3 and 4 months respectively

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranibizumab 0.5 mg (Type: EXPERIMENTAL): PRN intravitreal injection
- Sham injection (Type: SHAM_COMPARATOR): As of Month 3, ranibizumab 0.5 mg PRN intravitreal injections

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Topical Tranexamic Acid Use on Granulating Wounds Following Mohs Micrographic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All adult (18 years or older) patients presenting for Mohs micrographic surgery (MMS) for the treatment of melanoma or nonmelanoma skin cancer (NMSC) with a wound that will be healing by granulation~Exclusion Criteria:~* Patients must not be pregnant or breastfeeding.~* Patients must not have a known allergic reaction or sensitivity to TXA~* Patient must not have an international normalized ratio (INR) out of therapeutic range if on warfarin.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Topical application of tranexamic acid to granulating wound defect status post Mohs micrographic surgery.
- Placebo (Type: PLACEBO_COMPARATOR): Topical application of normal saline to granulating wound defect status post Mohs micrographic surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Leflunomide for Maintenance of Remission in IgG4 Related Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age between 18 and 80 years.~2. Diagnosis of IgG4-RD according to either Consensus statement on the pathology of IgG4-related disease (for those who have undergone biopsies) or 2011 Comprehensive diagnostic criteria for IgG4-related disease. Both of the two criteria for diagnosis are specified below.~(1)Consensus statement on the pathology of IgG4-related disease~1. Histopathologic features consisting of dense lymphoplasmacytic infiltrate, fibrosis(usually storiform in character)and/or obliterative phlebitis within involved organs.~2. Either an elevated IgG4+/IgG+cell ratio of \>40% within the affected organs or elevated IgG4-bearing plasma cells per high-power field is necessary. The cut-off number of IgG4-bearing plasma cells per high-power field is different depending upon the types of affected organs and specimens(through surgery or needle puncture biopsy).~(2)2011 Comprehensive diagnostic criteria for IgG4-related disease~1. Clinical examination showing characteristic diffuse/localized swelling or masses in single or multiple organs.~2. Hematological examination shows elevated serum IgG4 concentrations(135 mg/dl).~3. Histopathologic examination shows marked lymphocyte and plasmacyte infiltration and fibrosis or Infiltration of IgG4+ plasma cells(ratio of IgG4+/IgG+ cells \> 40% and \>10 IgG4+ plasma cells/HPF).~   Definite: a + b + c,Probable: a + c,Possible: a + b~4. Excluded from malignant tumors of each organ (e.g. cancer, lymphoma) and similar diseases (e.g. Sjögren's syndrome, primary sclerosing cholangitis, Castleman's disease, secondary retroperitoneal fibrosis, Wegener's granulomatosis, sarcoidosis, Churg-Strauss syndrome) by additional histopathological examination.~5. Even when patients cannot be diagnosed using the Comprehensive diagnostic criteria, they may be diagnosed using organ-specific diagnostic criteria for IgG4-RD, such as Diagnostic criteria for IgG4-Mikulicz's disease.~Exclusion Criteria:~1. Subjects having received steroids or immunosuppressants in recent 3 months will be excluded.~2. Subjects who were hypersensitive to leflunomide will be excluded.~3. ALT and/or AST is more than two folds of the upper limit of relevant reference value at baseline.~4. WBC is less than 3×10\*9/L at baseline.~5. Female patients who are pregnant or breastfeeding.~6. Known significant concurrent medical disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Prednisone (Type: EXPERIMENTAL): Prednisone mono-therapy
- Prednisone and Leflunomide (Type: EXPERIMENTAL): Prednisone and Leflunomide combination therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Observational Study to Evaluate LDL-C Lowering Effect of Ezetimibe (0653-070)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Men or women \>18 and \<80 years of age~* Patients receiving statin therapy for a minimum period of 6 weeks prior to visit 1~* Female patients receiving hormone therapy (including hormone replacement therapy, any estrogen antagonist/agonist, or oral contraceptives) if maintained on a stable dose and regimen for at least 8 weeks prior to visit 1 and if willing to continue the same regimen throughout the study~* Liver enzyme levels less than or equal to 1.5 times the upper limit of normal with no active liver disease and CPK less than or equal to 1.5 times upper limit of normal at visit 1~Exclusion Criteria:~* Cardiovascular medications, such as beta-blockers, calcium-channel blockers,~angiotensin ii receptor antagonists or anticoagulants (i.e., warfarin) unless~treated with a stable regimen for at least 6 weeks prior to randomization and~patient agrees to remain on constant regimen for the duration of the study~* Patients on amiodarone hydrochloride will also be excluded~* General weight less than 50% of ideal body weight according to the 1983 metropolitan height and weight tables or weighing less than 100 lbs (45 kg)~* Hypersensitivity to HMG-COA reductase inhibitors~* Patient has congestive heart failure defined by nyha class III or IV, uncontrolled cardiac arrhythmias, unstable angina pectoris, or myocardial infarction; coronary artery bypass surgery, or angioplasty within 3 months of visit 1~* Taking lipid-lowering agents including fish oils, cholestin, bile-acid sequestrants~and niacin (grater than 200 mg/day) taken within 6 weeks and fibrates taken within 8 weeks prior to visit 1~* Taking medications that are potent inhibitors of cyp3a4, including cyclosporine,~systemic itraconazole or ketoconazole, erythromycin or clarithromycin,~nefazodone, verapamil and protease inhibitors~* Consumption of greater than 250 ml of grapefruit juice/day~* Taking oral corticosteroids unless used as replacement therapy for pituitary/adrenal disease and on a stable regimen for at least 6 weeks prior to visit 1~* Treatment with psyllium, other fiber-based laxatives, and/or OTC therapies~known to affect serum lipid levels, phytosterol margarines, unless treated with~a stable regimen for at least 6 weeks prior to visit 1 and patient agrees to remain on constant regimen for the duration of the study~* Women who are pregnant or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent Paroxysmal Nocturnal Hemoglobinuria (PNH)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants between 2 and 17 years of age;~* Diagnosed with PNH;~* Participants with ≥ 5% glycosylphosphatidylinositol-deficient red blood cells or granulocytes as confirmed by flow cytometry;~* Participants must have shown evidence of hemolytic anemia as documented by lactate dehydrogenase greater than the upper limit of normal or at least 1 transfusion in the past 2 years for anemia or anemia related symptoms;~* Written informed consent from a parent/guardian;~* Negative pregnancy test for females of child bearing potential at screening;~* Sexually active females must have documented a reliable and medically approved method of contraception;~* Participant must have been vaccinated against N. men, S. pneumo, and H. influ at least 14 days prior to study drug initiation or received antibiotics for 14 days after the vaccinations.~Exclusion Criteria:~* Prior eculizumab treatment;~* Presence or suspicion of active bacterial infection at baseline;~* Participation in another concurrent clinical study within at least 30 days prior to screening;~* History of meningococcal/pneumococcal/gonococcal disease;~* Pregnant, breast feeding, or intending to conceive during the study including the safety follow-up visits;~* Any other condition that could increase the participant's risk or confound the outcome of the study.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Eculizumab (Type: EXPERIMENTAL): Eculizumab was administered as an IV infusion for 12 weeks. All participants weighed more than 45 kg and received the following weight-based dosing regimen: induction/loading = 600 milligram (mg) weekly x 4; maintenance = 900 mg at Week 5; 900 mg every 2 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Anglo-Scandinavian Cardiac Outcomes Trial: Post Trial Follow-Up Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Surviving ASCOT participants from the participating UK sites~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- ASCOT participants amlodipine (Type: None): It is follow up group from the ASCOT study, after treatment with amlodipine for 5.5 years. No treatment only follow up.
- ASCOT participants atenolol (Type: None): It is follow up group from the ASCOT study, after treatment with atenolol for 5.5 years. No treatment only follow up.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia Areata

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients between 18 to 75 years of age.~* Patients with a diagnosis of patch type alopecia areata.~* Patients will have \>30% and \<95% total scalp hair loss at baseline as measured using the SALT score. Two patients with current episodes of alopecia totalis/universalis may be included in this study.~* Duration of hair loss greater than 3 months.~* No evidence of regrowth present at baseline.~* Patients may be naïve to treatment or unresponsive to intralesional (IL) steroids or other treatments for alopecia areata.~Exclusion Criteria:~* Patients with a history of or active skin disease on the scalp such as psoriasis or seborrheic dermatitis.~* Patients in whom the diagnosis of alopecia areata is in question.~* Patients with active medical conditions or malignancies (except adequately treated basal or squamous cell carcinoma) that in the opinion of the investigator would increase the risks associated with study participation, including patients with a history of recurrent infections.~* Women of childbearing potential who are unable or unwilling to use two forms of birth control for the study duration.~* Women who are pregnant or nursing.~* Patients known to be HIV or hepatitis B or C positive.~* Patients with history or evidence of hematopoietic abnormality.~* Patients with \<200K platelet count at baseline.~* Patients with history or evidence of renal or hepatic impairment.~* Patients with history of immunosuppression or history of recurrent serious infections.~* Patients unwilling or unable to discontinue treatments known to affect hair regrowth in AA.~* Patients taking any medication considered a strong CYP3A4 inhibitor who is unable or unwilling to stop this medication for the duration of the study.~* Patients receiving treatment deemed to affect alopecia areata within 2 weeks to one month of baseline visit depending on the specific treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Ruxolitinib (Type: EXPERIMENTAL): A fixed dose of ruxolitinib (20mg) will be self-administered orally twice daily for 12 to 24 weeks. Dosing may be decreased or held if needed due to adverse effects.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age at least 18 years.~2. Documented evidence of NSCLC (locally advanced, unresectable, Stage III)~3. Patients must have received at least 2 cycles of platinum-based chemotherapy concurrent with radiation therapy.~4. World Health Organisation (WHO) Performance Status of 0 to 1.~5. Estimated life expectancy of more than 12 weeks.~Exclusion Criteria:~1. Prior exposure to any anti-PD-1 or anti-PD-L1 antibody.~2. Active or prior autoimmune disease or history of immunodeficiency.~3. Evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses or active infections including hepatitis B, C and HIV.~4. Evidence of uncontrolled illness such as symptomatic congestive heart failure, uncontrolled hypertension or unstable angina pectoris.~5. Any unresolved toxicity CTCAE \>Grade 2 from the prior chemoradiation therapy.~6. Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- MEDI4736 (Type: EXPERIMENTAL): MEDI4736 (intravenous infusion)
- PLACEBO (Type: PLACEBO_COMPARATOR): Placebo (matching placebo for intravenous infusion)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Behavioral and Pharmacological Treatment for Insomnia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Subjective complaint of difficulties initiating or maintaining sleep, accompanied by marked distress or daytime impairments due to insomnia~* Sleep difficulties present 3 nights or more per week and lasting for more than 6 months~Exclusion criteria:~* Major medical or psychiatric problems

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics/Pharmacodynamics of NOX-H94 in the Human Endotoxemia Model

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* BMI between 18 and 30 kg/m², with a lower limit of body weight of 50 kg~* Healthy as determined by medical history, physical examination, vital signs, 12 lead electrocardiogram, and clinical laboratory parameters~* Serum iron and red blood parameters Hb, MCV, ferritin, serum iron, and total iron binding capacity within reference range~Main Exclusion Criteria:~* Use of any medication, recreational drugs or anti-oxidant vitamin supplements within 7 days~* Use of caffeine, nicotine, or alcohol within 1 day~* Previous participation in a trial where LPS was administered~* Surgery or trauma with significant blood loss or blood donation within 3 months~* History, signs or symptoms of cardiovascular disease (vaso-vagal collapse or of orthostatic hypotension, Resting pulse rate ≤45 or ≥100/min, Hypertension, Hypotension, ECG conduction abnormalities)~* Renal impairment: plasma creatinine \>120 µmol/L~* Liver function tests (alkaline phosphatase, AST, ALT and γ-GT) outside of the reference range or total bilirubin \>20 µmol/L~* Hemoglobin or iron parameters (iron, transferring saturation, ferritin) outside of the reference ranges~* History of asthma~* Immuno-deficiency~* Positive test of HIV type 1/2 antibodies, HBs antigen, HBc antibodies and HCV antibodies unless antibody titer is induced by vaccination~* CRP \> reference range or clinically significant acute illness, including infections, within 2 weeks~* Treatment with investigational drugs or participation in any other clinical trial within 30 days prior to study drug administration~* Known or suspected of not being able to comply with the trial protocol~* Inability to personally provide written informed consent and/or take part in the study

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- NOX-H94 (Type: EXPERIMENTAL): Single dose of NOX-H94
- Placebo (Type: PLACEBO_COMPARATOR): Single dose of placebo control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Acute Effects of Inorganic Nitrite on Cardiovascular Hemodynamics in Heart Failure With Preserved Ejection Fraction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled to undergo a cardiac catheterization procedure.~* Clinical symptoms of shortness of breath and fatigue~* Normal left ventricular ejection fraction (≥50%)~* Elevated left ventricular filling pressures at cardiac catheterization (defined as resting pulmonary capillary wedge pressure (PCWP)\>15 mmHg and/or PCWP≥25 mmHg during exercise)~Exclusion Criteria:~* Systolic BP \<120 mmHg~* Prior nitrate therapy (within previous 2 weeks)~* Glucose 6-phosphate dehydrogenase (G6PD) deficiency~* Other non-HFpEF specific causes of heart failure such as significant valvular disease (\>moderate left-sided regurgitation, \>mild stenosis), severe pulmonary disease, unstable coronary disease or coronary spasm, primary renal or hepatic disease, constrictive pericarditis, or infiltrative, restrictive, or hypertrophic cardiomyopathies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nitrite (Type: EXPERIMENTAL): Study drug (NaNO_2 50 mcg/kg/min) will be infused for 5 minutes during the cardiac catheterization procedure.
- Saline (Type: PLACEBO_COMPARATOR): Saline Placebo for Nitrite will be infused for 5 minutes during the cardiac catheterization procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Dexmedetomidine Premedication on Emergence Agitation After Strabismus Surgery in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* aged2-6 yr, with American Society of Anesthesiologists physical status I or II, scheduled to undergo strabismus surgery during general anesthesia~Exclusion Criteria:~* mental disease, neurologic disease, treatment with sedatives, full stomach, or indication for rapid sequence induction.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine group (Type: EXPERIMENTAL): The dexmedetomidine group received intranasal dexmedetomidine 2mcg/kg premedication 45 min and oral saline 30 min before induction of anaesthesia
- Midazolam group (Type: ACTIVE_COMPARATOR): The midazolam group received intranasal saline 45 min and oral midazolam 0.5 mg/kg 30 min before induction of anaesthesia.
- Placebo Group (Type: PLACEBO_COMPARATOR): The Placebo group received intranasal saline premedication 45 min and oral saline 30 min before induction of anaesthesia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete